MedTrace Logo

Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

NCT02779101 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2016-06-22

No results posted yet for this study

Summary

In summary, there is a high medical need for patients suffering from recurrent/progressive PCNSL. Targeting the PD-1 pathway may represent a very promising novel approach for the treatment of these patients.

Conditions

Interventions

DRUG

pembrolizumab

Pembrolizumab 200 mg every 3 weeks

Sponsors & Collaborators

  • Prof. Dr. Matthias Preusser

    lead OTHER

Principal Investigators

  • Matthias Preusser, MD · MU Vienna, Dep. f. Internal medicine I, Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-06-30
Completion
2019-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02779101 on ClinicalTrials.gov